Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 377 participants.
Also called NCT01652716
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 377 participants
- Sponsor
- Registry
-
NCT01652716
-
- Other papers using this trial's data
- Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes
- Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01652716. Randomized; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-08 (actual). Results posted on 2015-09-16.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes
- Acronym
- DURATION-NEO-1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Exenatide once weekly suspension
- Intervention (Drug)
- Exenatide twice daily
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct01652716- Content hash
9d1b52884fc0cb726a6746f1a3bcbd97a2a30aca430acc9d54a26e39f0a0bbc7